Cranbrook Wealth Management’s Pfizer PFE Stock Holding History

Cranbrook Wealth Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109K	Hold	4,512	–	–	0.02%	158
2026 Q1	$127K	Hold	4,512	–	–	0.03%	144
2025 Q4	$112K	Hold	4,512	–	–	0.02%	157
2025 Q3	$115K	Hold	4,512	–	–	0.02%	156
2025 Q2	$109K	Hold	4,512	–	–	0.02%	156
2025 Q1	$114K	Sell	4,512 -122	-3%	-$3.19K	0.03%	139
2024 Q4	$123K	Hold	4,634	–	–	0.03%	137
2024 Q3	$134K	Buy	4,634 +9	+0.2%	+$263	0.03%	134
2024 Q2	$129K	Hold	4,625	–	–	0.03%	132
2024 Q1	$128K	Hold	4,625	–	–	0.03%	113
2023 Q4	$133K	Buy	4,625 +260	+6%	+$7.86K	0.04%	108
2023 Q3	$145K	Hold	4,365	–	–	0.04%	98
2023 Q2	$160K	Hold	4,365	–	–	0.04%	101
2023 Q1	$178K	Sell	4,365 -125	-3%	-$5.4K	0.05%	91
2022 Q4	$230K	Sell	4,490 -50	-1%	-$2.4K	0.06%	86
2022 Q3	$199K	Buy	4,540 +261	+6%	+$12.7K	0.05%	96
2022 Q2	$224K	Hold	4,279	–	–	0.06%	93
2022 Q1	$221K	Sell	4,279 -235	-5%	-$12.2K	0.05%	97
2021 Q4	$267K	Sell	4,514 -160	-3%	-$7.93K	0.06%	93
2021 Q3	$201K	Buy	4,674 +260	+6%	+$11.5K	0.05%	100
2021 Q2	$173K	Hold	4,414	–	–	0.04%	106
2021 Q1	$160K	Hold	4,414	–	–	0.04%	109
2020 Q4	$162K	Sell	4,414 -238	-5%	-$8.73K	0.04%	100
2020 Q3	$162K	Hold	4,652	–	–	0.05%	92
2020 Q2	$144K	Hold	4,652	–	–	0.04%	93
2020 Q1	$144K	Hold	4,652	–	–	0.05%	88
2019 Q4	$173K	Hold	4,652	–	–	0.05%	89
2019 Q3	$159K	Hold	4,652	–	–	0.05%	92
2019 Q2	$191K	Sell	4,652 -275	-6%	-$10.9K	0.06%	84
2019 Q1	$199K	Sell	4,927 -168	-3%	-$6.73K	0.06%	76
2018 Q4	$211K	Sell	5,095 -169	-3%	-$7.02K	0.07%	71
2018 Q3	$220K	Hold	5,264	–	–	0.08%	64
2018 Q2	$181K	Hold	5,264	–	–	0.07%	66
2018 Q1	$177K	Hold	5,264	–	–	0.07%	69
2017 Q4	$181K	Hold	5,264	–	–	0.07%	69
2017 Q3	$178K	Hold	5,264	–	–	0.07%	67
2017 Q2	$168K	Hold	5,264	–	–	0.07%	68
2017 Q1	$171K	Sell	5,264 -73	-1%	-$2.3K	0.08%	60
2016 Q4	$164K	Hold	5,337	–	–	0.08%	63
2016 Q3	$172K	Hold	5,337	–	–	0.09%	59
2016 Q2	$178K	Sell	5,337 -64	-1%	-$2.04K	0.09%	58
2016 Q1	$152K	Hold	5,401	–	–	0.08%	62
2015 Q4	$165K	Hold	5,401	–	–	0.09%	57
2015 Q3	$161K	Hold	5,401	–	–	0.09%	54
2015 Q2	$172K	Sell	5,401 -488	-8%	-$15.9K	0.1%	56
2015 Q1	$194K	Sell	5,889 -17	-0.3%	-$540	0.11%	53
2014 Q4	$175K	Hold	5,906	–	–	0.11%	56
2014 Q3	$166K	Buy	5,906 +505	+9%	+$14.2K	0.11%	49
2014 Q2	$152K	Hold	5,401	–	–	0.1%	52
2014 Q1	$165K	Sell	5,401 -3,162	-37%	-$94.3K	0.12%	47
2013 Q4	$249K	Buy	+8,563	New	+$249K	0.17%	54

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cranbrook Wealth Management's PFE Position: Q2 2026 in Review

Cranbrook Wealth Management held its Pfizer (PFE) position steady in Q2 2026 at 4,512 shares worth $109K. The position accounts for 0.02% of the portfolio, ranked #158.

Cranbrook Wealth Management first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $267K in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Cranbrook Wealth Management held 4,512 shares of Pfizer worth $109K as of Q2 2026.
Cranbrook Wealth Management left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.02% of Cranbrook Wealth Management's portfolio in Q2 2026, its #158 holding.
Cranbrook Wealth Management first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
Cranbrook Wealth Management's Pfizer position peaked at $267K in Q4 2021.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Cranbrook Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.